F Mion, A Géloén, E Agosto, Y Minaire – 1 March 1996 – In animal models, conflicting results on the effect of cirrhosis on glucose metabolism have been reported. The use of various toxins as well as differences in experimental protocols may be responsible for these controversial data. However, differences may be also be explained by the fact that glucose metabolism has been evaluated following different time intervals after cessation of the toxic injury.

R Dumaswala, D Berkowitz, J E Heubi – 1 March 1996 – Experimental cholestasis induced by ligation of the common bile duct results in morphological and functional changes in the rat hepatocyte. The aim of this study was to evaluate the adaptive response of the transport process involved in the enterohepatic circulation of bile salts to obstructive cholestasis. Male Sprague‐dawley rats with common bile duct ligation were killed after 48 and 72 hours. Portal and systemic blood and duodenal aspirates were collected.

John S. Radomski, Michael J. Moritz, Vincent T. Armenti, Santiago J. Muñoz – 1 March 1996

Martin Hertl, Todd K. Howard, Jeffrey A. Lowell, Surendra Shenoy, P. Robert C. Harvey, Steven M. Strasberg – 1 March 1996 – Liver core temperature during organ procurement, storage, and rewarming has not been reported in human orthotopic liver transplantations (OLT). We have shown in the rat that optimal temperature for liver storage is not 4°C but 0°C to 1°C. Therefore, a study was undertaken in humans and in pigs to determine the pattern of temperature change during OLT.

Kenneth L. Croutch, Roy L. Gordon, Ernest J. Ring, Robert K. Kerlan, Jeanne M. Laberge, John P. Roberts – 1 March 1996 – Transcatheter arterial embolization is widely used to treat life‐threatening iatrogenic hemobilia, although in the transplanted liver its use has only been reported in two cases. To evaluate more fully whether transcatheter embolization is safe and effective in transplant recipients, we retrospectively reviewed eight cases of severe hemobilia. These occurred after 128 percutaneous transhepatic biliary drainage procedures performed during a 6‐year period.

Stephen H. Caldwell, Michael Sue, James H. Bowden, Rolland C. Dickson, Carolyn J. Driscoll, Paul Yeaton, William C. Stevenson, Michael B. Ishitani, Christopher S. McCullough, Timothy L. Pruett, Mark A. Lovell – 1 March 1996 – Recurrence of hepatitis C virus (HCV) after liver transplantation is common and is associated with high blood levels of HCV RNA. Higher blood levels of HCV may promote body fluid expression of the virus. We tested 152 body fluid specimens from 33 patients with chronic hepatitis C, 21 of whom had undergone prior liver transplantation.

Robert G. Gish, Nancy L. Ascher – 1 March 1996

L Alric, E Pinelli, G Carrera, J P Vinel, M Beraud, M Duffaut, J P Pascal, B Pipy – 1 March 1996 – The aim of the present study was to assess the mechanism of 5‐lipoxygenase metabolites (LT) secretion by peritoneal macrophages in rats wih CC14 induced cirrhosis. After stimulation with calcium ionophore A23187 or opsonized zymosan, [3H] arachidonic acid labeled macrophages from cirrhotic rats presented a significantly greater secretion of LT than macrophages from healthy controls.

Jean Vix, Philippe Compagnon, Jean‐Paul Beller, Daniel Jaeck, Philippe Wolf, Karim Boudjema – 1 March 1996 – The introduction of University of Wisconsin solution has made liver transplantation a semi‐elective procedure. However, many studies have suggested that cold storage must not exceed 12 hours to avoid ischemic‐type biliary complications, to reduce the incidence of primary nonfunction and to improve graft and patient survival. The aim of this study was to compare the function of livers transplanted as soon as possible after the liver was harvested and those preserved overnight.

Y Haruna, K Saito, S Spaulding, M A Nalesnik, M A Gerber – 1 March 1996 – Intermediate filament proteins have been reported to be expressed in a cell lineage‐specific manner during morphogenesis. We studied the expression of cytokeratin (CK)14, CK19, and vimentin and of the hepatocyte‐specific HepPar1 antigen during the development of human liver.